US Patent

US8653260 — Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Composition of Matter · Assigned to Merck Sharp and Dohme LLC · Expires 2029-04-02 · 3y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of Formula (I) and their use in treating or preventing diseases mediated by the activation of beta 3 adrenergic receptors.

USPTO Abstract

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

Drugs covered by this patent

Patent Metadata

Patent number
US8653260
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-04-02
Drug substance claim
Yes
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.